Nutritional Status Evaluation in Underweight Indonesian Children Receiving 0.89 kcal/mL Milk Powder - Site Makassar (GROW)

November 11, 2026 updated by: PT Equilab International

Evaluation of the Nutritional Status of Underweight Indonesian Children Receiving 0.89 kcal/mL Milk Powder: An Open-Label, Single-Arm, Prospective Study (GROW Study)

The goal of this clinical trial is to learn whether daily use of GROPLUS, an energy-dense milk powder, can improve growth in Indonesian children aged 24 to 48 months who are underweight. The main question it aims to answer is:

- Does taking Investigational Product (milk-product) for 6 months improve children's weight relative to their age?

Researchers will also assess changes in height, weight relative to height, body mass index, head size, growth rate, digestive comfort, and safety during the study.

Participants will:

  • Complete a 7-day feeding trial to check whether they can tolerate and accept the study product.
  • Drink two servings of Investigational product (milk-product) each day for 6 months.
  • Visit the study site regularly for growth measurements and other assessments.
  • Have their digestive symptoms, product use, and any health problems monitored during the study.

The study will enroll at least 74 children. All participants will receive GROPLUS, and there is no placebo or comparison group.

Study Overview

Status

Recruiting

Conditions

Detailed Description

This study evaluates the effect of daily supplementation with Investigational Product (milk-based), an energy-dense milk powder providing 0.89 kcal/mL, on the nutritional status and growth of Indonesian children aged 24 to 48 months who are underweight.

The study uses an open-label, single-arm, prospective interventional design. All enrolled participants receive the same study product, and there is no randomization, blinding, placebo, or non-intervention control group. Changes during the intervention are evaluated by comparing each participant's measurements with their baseline values. The study design was selected because the study population consists of children with moderate underweight, and withholding nutritional support through a placebo or non-intervention group was considered inappropriate in the study protocol.

Before enrollment, potentially eligible children complete a 7-day feeding trial. During this period, caregivers prepare and provide the study product according to standardized instructions and record daily intake, leftovers, and gastrointestinal symptoms. The feeding trial is used to assess initial product acceptance and gastrointestinal tolerance. Children who successfully complete the feeding trial and remain eligible proceed to the baseline assessment and the 6-month intervention period.

During the intervention period, participants consume two servings of Investigational Product (milk-based) each day for approximately 6 months. The study product is dispensed regularly, and caregivers record daily product consumption and gastrointestinal symptoms in study diaries. Study staff review product use and returned product packaging to assess adherence. Safety monitoring for adverse events and serious adverse events continues throughout the study.

Growth and nutritional status are assessed during scheduled study visits using anthropometric measurements. Additional assessments are used to characterize gastrointestinal tolerance, salivary cortisol, the home environment and caregiving stimulation, child behavioral and emotional functioning, dietary patterns, product acceptability, and caregiver satisfaction. Safety and tolerability are assessed throughout the intervention, including monitoring of adverse events and common illnesses such as upper respiratory tract infection, diarrhea, and fever.

The study plans to enroll at least 74 children, with recruitment distributed between study sites in Manado and Makassar. An interim analysis is planned around Month 3 to review data completeness, protocol adherence, participant safety, and overall study progress. The interim analysis is descriptive and exploratory and is not intended for formal efficacy hypothesis testing.

The study is intended to provide information on the potential effect of 6 months of Investigational Product (Milk-based) supplementation on growth and nutritional status, while also describing gastrointestinal tolerance, safety, product acceptability, and other related nutritional and developmental measures in this population.

Study Type

Interventional

Enrollment (Estimated)

37

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • South Sulawesi
      • Makassar, South Sulawesi, Indonesia, 90552
        • Recruiting
        • Klinik Rezky Tiara Makassar
        • Contact:
          • Martira Maddeppungeng, Sp.A,Subsp.TKPS(K)
          • Phone Number: +62 813-4290-3666
          • Email: martira711@yahoo.com
        • Principal Investigator:
          • Martira Maddeppungeng, Sp.A,Subsp.TKPS(K)
        • Sub-Investigator:
          • Merlyn M Astari, Sp.A (K)
        • Sub-Investigator:
          • Aidah Juliaty A Baso, Sp.A,Subsp.NPM(K), Sp.GK

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

2 years to 4 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Children aged 24 to 48 months at the time of enrollment.
  • Classified as underweight according to the World Health Organization Growth Standards 2006, with a Weight-for-Age Z-score below -2.
  • Willing to participate and consume the study product, a milk powder providing 0.89 kcal/mL, during the 7-day feeding trial and 6-month intervention period.
  • Parent or legal guardian has provided signed informed consent before participation
  • No plan to relocate or move residence within the next 8 months during the study period
  • Able and willing to comply with study procedures, including scheduled visits, dietary recalls, and product consumption recording
  • Completed the 7-day feeding trial and demonstrated tolerance of the study product without aversion, intolerance, or allergic reaction, as confirmed by the study physician
  • Parent or primary caregiver has adequate literacy to understand study instructions, with a minimum education level of completed senior high school.

Exclusion Criteria:

  • History of preterm birth, defined as gestational age below 37 weeks
  • Birth weight below 2,500 g or above 4,000 g
  • Weight-for-Height Z-score below -2 standard deviations, indicating moderate acute malnutrition
  • Height-for-Age Z-score below -2, indicating stunting
  • Presence of historic of chronic or infectious diseases, including tuberculosis, congenital heart disease, or other acute or chronic illness that may affect nutritional intake or growth
  • Diagnosed cow's milk protein allergy or lactose intolerance by a healthcare professional
  • Currently participating in another clinical or nutrition intervention study
  • Presence of signs suggestive of anemia, identified through non-invasive physical examination by a pediatric clinician
  • Inability to tolerate or complete the 7-day feeding trial, including moderate to severe gastrotinestinal symptoms related to the study product or inability to complete 7 full days of product consumption
  • Any condition that, in the investigator's judgement, makes the child unsuitable for the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: GROPLUS Milk Powder

Participants will receive GROPLUS milk powder with an energy density of 0.89 kcal/mL for 6 months. Participants will consume two servings of the study product each day according to standardized preparation and administration instructions. Study staff will monitor product use, gastrointestinal tolerance, adherence, and safety throughout the intervention period.

GROPLUS is an energy-dense milk powder providing 0.89 kcal/mL when prepared according to the study instructions. Participants will consume two servings per day for approximately 6 months. The product will be prepared and administered according to standardized study instructions, with product use and compliance monitored throughout the intervention period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Weight-for-Age Z-score from Baseline to Month 6
Time Frame: From baseline (Month 0) to Month 6

Change in Weight-for-Age Z-score (WAZ), calculated using the 2006 World Health Organization Child Growth Standards. WAZ will be determined from participants' weight and age measurements at baseline and Month 6. The change will be calculated as the difference between the Month 6 and baseline WAZ values and evaluated against a predefined minimal clinically important difference of 0.20 Z-score.

From baseline (Month 0) to Month 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Height-for-Age Z-score from Baseline to Month 6
Time Frame: From baseline (Month 0) to Month 6

Change in Height-for-Age Z-score (HAZ), calculated using the 2006 World Health Organization Child Growth Standards. Height will be measured at baseline and Month 6, and the change in HAZ will be assessed to characterize linear growth.

From baseline (Month 0) to Month 6
Change in Body Mass Index-for-Age Z-score from Baseline to Month 6
Time Frame: From baseline (Month 0) to Month 6

Change in Body Mass Index-for-Age Z-score (BAZ), calculated from body mass index measurements standardized using World Health Organization age-based reference values. The change will be assessed between baseline and Month 6.

From baseline (Month 0) to Month 6
Change in Head Circumference-for-Age Z-score from Baseline to Month 6
Time Frame: From baseline (Month 0) to Month 6

Change in Head Circumference-for-Age Z-score (HCZ), calculated using the 2006 World Health Organization Child Growth Standards. Head circumference will be measured at baseline and Month 6.

From baseline (Month 0) to Month 6
Weight Gain Velocity from Baseline to Month 6
Time Frame: From baseline (Month 0) to Month 6

Rate of weight gain expressed in grams per month (g/month), calculated from serial body weight measurements collected during the study. Weight velocity will be assessed between baseline and Month 6.

From baseline (Month 0) to Month 6
Height Gain Velocity from Baseline to Month 6
Time Frame: From baseline (Month 0) to Month 6

Rate of height gain expressed in millimeters per month (mm/month), calculated from serial height measurements collected during the study. Height velocity will be assessed between baseline and Month 6.

From baseline (Month 0) to Month 6
Change in Gastrointestinal Tolerance from Baseline to Month 6
Time Frame: From baseline (Month 0) to Month 6

Change in gastrointestinal tolerance assessed using the Toddler Gut Comfort Questionnaire (TGCQ). The assessment includes the total score and relevant domain scores reflecting gastrointestinal comfort during the study. Scores will be compared between baseline and Month 6.

From baseline (Month 0) to Month 6
Change in Salivary Cortisol Concentration from Baseline to Month 6
Time Frame: From baseline (Month 0) to Month 6

Change in salivary cortisol concentration, expressed in nmol/L, measured using saliva samples collected at baseline and Month 6. Salivary cortisol concentration will be determined using a validated Enzyme-Linked Immunosorbent Assay (ELISA).

From baseline (Month 0) to Month 6
Home Environment and Caregiving Stimulation Assessment
Time Frame: At baseline (Month 0), Month 3, and Month 6

Assessment of the home environment and caregiving stimulation using the Home Observation for Measurement of the Environment (HOME) Inventory. The assessment will characterize the home environment and caregiving stimulation at baseline, Month 3, and Month 6.

At baseline (Month 0), Month 3, and Month 6
Incidence and Frequency of Adverse Events and Common Infectious Illnesses
Time Frame: From baseline (Month 0) through Month 6

The incidence and frequency of adverse events during the intervention period, including common infectious illnesses such as upper respiratory tract infection, diarrhea, and fever. Adverse events will be monitored and documented throughout the intervention period.

From baseline (Month 0) through Month 6

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Child Behavioral and Emotional Functioning
Time Frame: At baseline (Month 0), Month 3, and Month 6

Change in child behavioral and emotional functioning assessed using the Child Behavior Checklist (CBCL). Assessments will be conducted at baseline, Month 3, and Month 6, including internalizing, externalizing, and total problem scores.

At baseline (Month 0), Month 3, and Month 6
Caregiver-Reported Child Liking of Product Appearance
Time Frame: Every 2 weeks from baseline through Month 6

Child's liking of the study product's appearance, as reported by the parent or caregiver using the study-specific Child Product Liking Questionnaire with a pictorial response scale. Responses are categorized as dislike (0), neutral (1), or like (2), with a possible score range of 0 to 2. Higher scores indicate greater liking. Results will be reported as the number and percentage of participants in each response category.

Every 2 weeks from baseline through Month 6
Caregiver-Reported Child Liking of Product Taste
Time Frame: Every 2 weeks from baseline through Month 6

Child's liking of the study product's taste, as reported by the parent or caregiver using the study-specific Child Product Liking Questionnaire with a pictorial response scale. Responses are categorized as dislike (0), neutral (1), or like (2), with a possible score range of 0 to 2. Higher scores indicate greater liking. Results will be reported as the number and percentage of participants in each response category.

Every 2 weeks from baseline through Month 6
Caregiver-Reported Child Liking of Product Texture
Time Frame: Every 2 weeks from baseline through Month 6

Child's liking of the study product's texture, as reported by the parent or caregiver using the study-specific Child Product Liking Questionnaire with a pictorial response scale. Responses are categorized as dislike (0), neutral (1), or like (2), with a possible score range of 0 to 2. Higher scores indicate greater liking. Results will be reported as the number and percentage of participants in each response category.

Every 2 weeks from baseline through Month 6
Parent or Caregiver Satisfaction with Product Use and Feeding Experience
Time Frame: Every 2 weeks from baseline through Month 6

Parent or caregiver satisfaction with the nutritional quality of the study product, assessed using the study-specific Parent/Caregiver Satisfaction Questionnaire. Responses are categorized as yes, neutral, no, or unwilling to respond. Results will be reported as the number and percentage of participants in each response category

Every 2 weeks from baseline through Month 6
Baseline Dietary Patterns and Macronutrient Intake
Time Frame: At baseline (Month 0)

Baseline habitual dietary patterns and macronutrient intake assessed using a validated Food Frequency Questionnaire (FFQ) before the 6-month supplementation period.

At baseline (Month 0)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 10, 2026

Primary Completion (Estimated)

March 31, 2027

Study Completion (Estimated)

May 31, 2027

Study Registration Dates

First Submitted

October 8, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no plan to share individual participant data (IPD) with other researchers. The study data will be maintained by the Sponsor and study team and will be used for the purposes described in the study protocol. Participant confidentiality and data privacy will be maintained.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe